Fiscal year 2025 represented a pivotal chapter for CSL Vifor, as CSL has adapted to an evolving competitive landscape and prepared for more than 30 planned product launches across the iron and nephrology portfolios. These launches are designed to significantly broaden CSL Vifor’s global impact and serve as key drivers of future growth and long‑term success. CSL Vifor’s commercial portfolio has remained focused on addressing substantial unmet medical needs, supporting patients worldwide who are living with chronic and rare conditions in iron deficiency and nephrology. In the iron portfolio, CSL Vifor has successfully and effectively navigated a dynamic and increasingly competitive iron market landscape, surpassing expectations through sustained volume growth of its leading intravenous (IV) iron therapy, FERINJECT®. Continued strong performance has been underpinned by strategic and operational initiatives, including agile tendering approaches, a robust launch momentum in new geographies, the inclusion of the pediatric indication in the Chinese National Reimbursement Drug List, meaningful product label enhancements and driving additional value for the CSL Vifor and CSL Behring offerings from Patient Blood Management. Despite these advances, the IV iron market remains under-developed with a limited number of eligible patients receiving the optimal iron replacement therapy. CSL Vifor remains committed to strengthening its leadership and competitive advantage in the iron therapy market and further expanding the market to address the significant unmet medical need. In nephrology, CSL Vifor has made notable progress in expanding its presence across the renal disease spectrum. The successful launches of FILSPARI®, TAVNEOS® and KAPRUVIA® have significantly enhanced CSL’s portfolio in this therapeutic area. CSL’s efforts reflect a comprehensive approach to chronic kidney disease (CKD), offering solutions that span from kidney damage prevention to treatment of complications and dialysis, emphasising rare nephrology. Most recently, England’s National Institute for Health and Care Excellence has recommended FILSPARI® as a treatment option for eligible IgA nephropathy patients, marking it as the first non-immunosuppressive dual-action therapy endorsed for this leading cause of kidney failure. These regulatory and health technology achievements underscore the strong clinical foundation and expanding access for FILSPARI®. The renal disease market is expected to grow particularly in the rare nephrology segment. This growth is driven by demographic trends such as an aging population, the increasing prevalence of CKD risk factors – including diabetes, hypertension, and cardiovascular disease – and the rising demand for innovative treatment options. Looking ahead, CSL continues to launch excellence in nephrology and to expand its position in the renal disease market. Strategic partnerships have remained a cornerstone of CSL Vifor’s growth model throughout fiscal year 2025. Internal and external collaborations continue to play a pivotal role in advancing CSL’s objectives. Joint efforts with CSL Behring have unlocked new opportunities, including the launch of FERINJECT® in Canada and the introduction of new vial sizes for ZEMAIRA® in the United States. Similarly collaboration with CSL Seqirus in Europe has leveraged CSL’s global capabilities while adapting to local market needs delivering meaningful value to patients and contributing to enterprise-wide sustainable growth. + READ MORE AT INVESTORS.CSL.COM CSL’s Businesses and Outlook US$2,234m CSL Vifor revenue 18 Performance
RkJQdWJsaXNoZXIy MjE2NDg3